CKD-501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CKD-501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks

Published:2013-09-12 Issue:12 Volume:34 Page:1271-1284
ISSN:0260-437X
Container-title:Journal of Applied Toxicology
language:en
Short-container-title:J. Appl. Toxicol.

Author:

Moon Kyoung-Sik¹²,Lee Ji-Eun³,Lee Hee Su⁴,Hwang In-Chang⁵,Kim Dal-Hyun⁵,Park Hyun-Kyu⁶,Choi Hyun-Ji⁶,Jo Woori⁶,Son Woo-Chan⁶,Yun Hyo-In²

Affiliation:

1. Division of Non-clinical Studies; Korea Institute of Toxicology (KIT); Daejeon Korea

2. Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine; Chungnam National University; Daejeon Korea

3. College of Veterinary Medicine; Chonnam National University; Gwangju Korea

4. Wallace H. Coulter Department of Biomedical Engineering; Georgia Institute of Technology; Atlanta Georgia USA

5. Chong Kun Dang Research Institute; CKD Pharmaceuticals Inc.; Kyunggi-do Korea

6. Asan Institute for Life Sciences and Department of Pathology; University of Ulsan College of Medicine, Asan Medical Center; Seoul Korea

Publisher

Wiley

Subject

Toxicology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jat.2918/fullpdf

Reference32 articles.

1. Current status of carcinogenicity assessment of peroxisome proliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential;Aoki;J. Toxicol. Pathol.,2007

2. Suppression of NF-kB and GSK-3b is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone;Ban;Chem. Biol. Interact.,2010

3. Enegery balance and food intake: the role of PPARγ gene polymorphisms;Cecil;Physiol. Behav.,2006

4. p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone;Duddy;Toxicol. Appl. Pharmacol.,1999

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model;European Journal of Pharmacology;2023-10

2. Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-04

3. Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-01

4. A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus;Diabetes & Metabolism Journal;2022-11-30

5. Lobeglitazone, A Peroxisome Proliferator-Activated Receptor-Gamma Agonist, Inhibits Papillary Thyroid Cancer Cell Migration and Invasion by Suppressing p38 MAPK Signaling Pathway;Endocrinology and Metabolism;2021-10-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3